Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
HematologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal for immunotherapy of cancer
- Publicado em
- 17 nov 2024
- Citações
- 37
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
Xiaojie Liang, Yufan Wang, Baiwei Luo, Bingyu Lin, WeiXiang Lu, Shengyu Tian, Dan Liu, Liang Wang
Descritores MeSH
- Multiple Myeloma
- Immunotherapy, Adoptive
- Antibodies, Bispecific
- Receptors, Chimeric Antigen
- Humans
- B-Cell Maturation Antigen
Veja também
Estudos relacionados
- A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
- Salvage Therapies After Anti-BCMA CAR-T Failure in Patients With Multiple Myeloma: A Meta-Analysis of Response Rates
- Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies
- Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis
- Perfis de segurança da terapia celular CAR-T em doenças autoimunes sistemáticas: uma revisão sistemática e análise